<DOC>
	<DOCNO>NCT00034385</DOCNO>
	<brief_summary>This study compare different way give drug ganciclovir valganciclovir kidney kidney pancreas transplant recipient determine effective dose valganciclovir protect cytomegalovirus ( CMV ) infection patient . One common viral infection follow organ transplant , CMV cause serious illness even death . Ganciclovir reduce incidence CMV disease kidney transplantation . The drug give either intravenously ( vein ) twice day mouth 3 time day . Valganciclovir convert ganciclovir body absorb bloodstream well oral ganciclovir . In transplant patient , single daily dose valganciclovir prevents CMV . Because advantage , transplant patient give valganciclovir instead ganciclovir prevent CMV infection . However , drug study kidney kidney transplant patient . This study provide dose information patient population . Patients 18 year age old kidney kidney pancreas transplant NIH Clinical Center may eligible study . Participants undergo follow treatment procedure : - Phase 1 - Treatment intravenous ganciclovir least 7 day transplantation . Sometime start phase 2 , patient provide 24-hour urine collection test kidney function . The day start phase 2 , cannula ( small needle ) insert arm vein 12 hour draw blood samples-one start ganciclovir infusion , 15 , 30 , 60 , 90 minute , 2 , 4 , 6 , 8 , 12 hour dose . - Phase 2 - Treatment oral valganciclovir day 7 21 day dose approximately equivalent intravenous ganciclovir . Sometime 4 21 day dose , patient blood sample morning take drug 0.5 , 1 , 1.5 , 2 , 4 , 6 , 8 , 12 , 24 hour dose . - Phase 3 - Treatment valganciclovir dose reduce half approximate oral ganciclovir dosing . After least 4 day dose , patient admit hospital 1 day blood sample drug dose 0.5 , 1 , 1.5 , 2 , 4 , 6 , 8 , 12 , 24 hour dose . Kidney function assess blood test within 2 day blood sampling . If kidney function within normal range , dose blood sample delayed kidney function return normal range . - Phase 4 - Treatment oral ganciclovir every 8 hour . After least 4 day regimen , patient admit hospital 1 day blood sample drug dose 0.5 , 1 , 1.5 , 2 , 4 , 6 , 8 hour dose . Kidney function estimate blood test within 2 day blood sampling . If kidney function within normal range , dose blood sample delayed kidney function return normal range . After complete phase 4 , patient continue valganciclovir daily oral ganciclovir treatment blood sample length time prescribe transplant surgeon .</brief_summary>
	<brief_title>Valganciclovir Prevent Cytomegalovirus Infection Kidney Kidney/Pancreas Transplant Recipients</brief_title>
	<detailed_description>Cytomegalovirus solid organ transplant recipient result significant morbidity mortality due concurrent immunosuppression . Traditionally intravenous follow oral ganciclovir use prevent treat cytomegalovirus infection disease transplant recipient . Recently new oral form ganciclovir , valganciclovir approve Food Drug Administration treatment CMV retinitis patient AIDS . Valganciclovir bioavailable require few daily dos low pill burden oral ganciclovir . In addition valganciclovir attain ganciclovir plasma level similar intravenous ganciclovir . This protocol test ability valganciclovir provide similar drug exposure ( area curve , AUC ) oral intravenous ganciclovir equivalent dos set kidney kidney-pancreas transplantation . Patients receive four different dosing/dosage form scheme . Intravenous ganciclovir 2.5mg/kg every 12 hour , usual treatment facility post surgery administer approximately 7 day ( phase I ) , patient receive valganciclovir 900 mg daily 7 21 day ( phase II ) , patient receive 450 mg daily least 4 day ( phase III ) , finally , ganciclovir 1000 mg every 8 hour least 4 day ( phase IV ) . Serial blood sample collect pharmacokinetic analysis change dose/dosage form ( phase ) . After completion study , patient maintain valganciclovir 450 mg daily CMV prophylaxis oral ganciclovir length time prescribe transplant surgeon . By characterize pharmacokinetics valganciclovir kidney/pancreas transplant patient , hop appropriate dosing prevent CMV disease limit toxicity may achieve .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>INCLUSION CRITERIA : Candidates receive kidney kidney/pancreas transplant Warren G. Magnuson Clinical Center require CMV prophylaxis . Willingness legal ability give inform consent . Estimated creatinine clearance ( use MDRD 4 variable equation ( 16 ) ) great equal 60ml/min/1.73m ( 2 ) 24 hour urine creatinine clearance great equal 60ml/min/1.73m ( 2 ) . EXCLUSION CRITERIA : Age le 18 year old . Pregnant ( pregnancy test part transplant protocol ) . Absolute neutrophil count le 500/mm ( 3 ) . Platelet count le 50,000/mm ( 3 ) . Severe anemia postoperatively , Hgb le 8.0 mg/dl despite erythropoetin therapy ( subject start erythropoetin iron supplementation post transplant ) . Hypersensitivity ganciclovir valganciclovir . The presence persistent diarrhea ( great equal 7 stool stool volume great 1 liter per day great equal 3 day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 20, 2008</verification_date>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Renal Transplant</keyword>
	<keyword>Valcyte</keyword>
	<keyword>Kidney Transplant</keyword>
</DOC>